直击业绩说明会丨东曜药业上市以来首次年度业绩扭亏,但“功臣”产品或将面临全国性集采

每日经济新闻
13 Mar

3月11日,东曜药业-B(01875.HK,股价1.95港元,市值15亿港元)发布2024年度业绩公告,公司实现全年营收10.98亿元,同比增长41%。其中产品销售收入为8.77亿元,同比增长39%;CDMO/CMO(医药外包)业务收入为2.07亿元,同比增长47%,其中ADC(抗体药物偶联物)项目收入占比86%。东曜药业称,业绩超预期的原因主要系核心产品朴欣汀(贝伐珠单抗注射液)销量的稳步增长。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10